Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Hood

Neurological Surgery Tulsa, OK Medical Doctor

NPI 1194875732 CMS profile 852566

1923 S Utica Ave, Ste 785, Tulsa, OK 74104

Open in the dashboard

General payments

$13,235

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Hood of Tulsa, OK is reported in the CMS Open Payments database as having received $13,235 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,923 68
2024 General $3,011 66
2023 General $2,122 37
2022 General $1,627 32
2021 General $2,175 36
2020 General $615 10
2019 General $762 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Hood
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Brian Hood were reported at $2,923. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Brian Hood Neurological Surgery median Middle half National median
2019 $762 $582 $138–$3,006 $163
2020 $615 $294 $76–$2,174 $114
2021 $2,175 $387 $105–$2,432 $132
2022 $1,627 $542 $139–$2,989 $149
2023 $2,122 $534 $145–$2,697 $160
2024 $3,011 $574 $155–$3,046 $164
2025 $2,923 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,556 65 payments
  2. Medtronic, Inc. $2,524 72 payments
  3. Abbott Laboratories $1,166 64 payments
  4. VB Spine LLC $764 10 payments
  5. Providence Medical Technology, Inc. $526 13 payments
  6. Medtronic USA, Inc. $506 7 payments
  7. Boston Scientific Corporation $497 11 payments
  8. 4WEB, Inc. $450 10 payments
  9. MML US, Inc. $238 4 payments
  10. Nevro Corp. $182 4 payments
  11. Other $1,826 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,950 310 payments
  2. Travel and Lodging $285 2 payments
Products named General payments · program years 2019–2025
  1. EVEREST SPINAL SYSTEM $1,532 27 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $1,444 39 payments
  3. MONTEREY AL $1,119 15 payments
  4. CASCADIA INTERBODY SYSTEM $580 5 payments
  5. N/A $468 7 payments
  6. SPINE TRUSS SYSTEM $450 10 payments
  7. PIVOX Oblique Lateral Spinal System $436 5 payments
  8. ProLift $391 5 payments
  9. WaveWriter Alpha Prime 16 $341 6 payments
  10. CAPRI CORPECTOMY CAGE SYSTEM $310 5 payments
  11. Other $7,092 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

391

Median for Neurosurgery: 83

Drug cost

$3,575

Median for Neurosurgery: $872

Branded share of claims

46%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 136 $1,549
Methocarbamol Generic 73 $641
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $409
Gabapentin Generic 41 $314
Pregabalin Generic 13 $164
Tizanidine Hcl Generic 11 $139
Tramadol Hcl Generic 25 $124
Acetaminophen-Codeine Acetaminophen With Codeine Brand 13 $97
Methylprednisolone Generic 11 $69
Meloxicam Generic 24 $37

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$193,775

Medicare's payments for the services billed

Medicare patients

405

Average age 75

Services billed

933

224 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 40%
Depression 32%
Diabetes 31%
Chronic kidney disease 25%
Osteoporosis 23%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record